

FIRST LIGHT 07 March 2022

RESEARCH

Greenpanel Industries | Target: Rs 595 | +26% | BUY

On a strong growth trajectory

SUMMARY

Greenpanel Industries

- GREENP well placed to capitalise on near-term MDF opportunity with management guiding for 15% volume growth in FY23E
- We maintain revenue/EBITDA/PAT CAGR estimates at 26%/37%/58% through to FY24 backed by better MDF utilisation and operating leverage
- Current valuations attractive at 18x FY24E EPS maintain BUY with unchanged TP of Rs 595

Click here for the full report.

Daily macro indicators

| Indicator | 02-Mar | 03-Mar | Chg (%) |
|---------------------------|---------|---------|----------------|
| US 10Y yield (%) | 1.88 | 1.84 | (4) |
| India 10Y yield (%) | 6.82 | 6.83 | 1 |
| USD/INR | 75.71 | 75.91 | (0.3) |
| Brent Crude (US\$/bbl) | 112.9 | 110.5 | (2.2) |
| Dow | 33,891 | 33,795 | (0.3) |
| Hang Seng | 22,344 | 22,467 | 0.6 |
| Sensex | 55,469 | 55,103 | (0.7) |
| India FII (US\$ mn) | 28-Feb | 02-Feb | Chg (\$ mn) |
| FII-D | (93.1) | (194.0) | (101.0) |
| FII-E | (547.7) | (535.7) | 12.0 |

Source: Bank of Baroda Economics Research

BOBCAPS Research researchreport@bobcaps.in





BUY
TP: Rs 595 | A 26%
GREENPANEL INDUSTRIES

Construction Materials

04 March 2022

On a strong growth trajectory

- GREENP well placed to capitalise on near-term MDF opportunity with management guiding for 15% volume growth in FY23E
- We maintain revenue/EBITDA/PAT CAGR estimates at 26%/37%/58%
 through to FY24 backed by better MDF utilisation and operating leverage
- Current valuations attractive at 18x FY24E EPS maintain BUY with unchanged TP of Rs 595

Ruchitaa Maheshwari researchreport@bobcaps.in

We organised a conference call with GREENP CFO, V Venkatramani to gain a perspective on the company's growth prospects and sector outlook. Key takeaways:

MDF volume growth guided at 15% in FY23E: During Q3FY22, GREENP increased MDF capacity by 20% to 660,000cbm via debottlenecking. The company looks poised to capitalise on the near-term growth opportunity from rising acceptance of MDF in the readymade furniture market and the absence of major capacity additions in the industry during FY23 (beyond Rushil Décor's 240,000cbm expansion which has already been absorbed and CPBI's upcoming 130,000cbm addition in H1FY23). Management expects MDF volumes of 575,000cbm in FY23.

Brownfield expansion planned at AP plant: The company plans to expand its Andhra Pradesh plant at a tentative capacity by 180,000cbm at a capex of ~Rs 4bn by Q4FY24. Per management, this new capacity will generate revenue to the tune of Rs 5.4bn-5.5bn at optimal capacity utilisation, expected in FY26.

Plywood margin to remain steady: In order to counter higher raw material costs, GREENP took a 4% price hike in Dec'21 (implemented mid-Jan'22) and 3% hike in January (implemented mid-Feb). The company is facing difficulties implementing these hikes, which also occur with a lag of 3-4 months. Nonetheless, management believes plywood operating margins will remain steady in the range of 11-11.5%.

Debt position improving: In FY21, net debt stood at Rs 3.7bn which was reduced to Rs 1.4bn in 9MFY22. Management expects the company to be net debt-free between Jun-Sep'22.

Robust growth outlook with attractive valuations; BUY: We expect ROCE to rise 16ppt to 24.4% over FY21-FY24 led by better utilisation, sharp profit improvement, higher FCF generation and subsequent debt reduction. We continue to model for a strong revenue/EBITDA/PAT CAGR of 26%/37%/58%. The stock is trading at 18x FY24E EPS, 35% lower than peer CPBI. We believe this valuation gap will narrow and retain BUY with a TP of Rs 595 set at 23x FY24E EPS.

Key changes

| , | | | |
|---|--------|------------|--|
| | Target | Rating | |
| | < ▶ | ∢ ▶ | |

| Ticker/Price | GREENP IN/Rs 472 |
|------------------|------------------|
| Market cap | US\$ 760.4mn |
| Free float | 47% |
| 3M ADV | US\$ 2.2mn |
| 52wk high/low | Rs 539/Rs 150 |
| Promoter/FPI/DII | 53%/4%/43% |

Source: NSE | Price as of 4 Mar 2022

Key financials

| FY21A | FY22E | FY23E |
|--------|--|--|
| 10,208 | 15,265 | 18,348 |
| 2,077 | 3,750 | 4,684 |
| 808 | 1,965 | 2,662 |
| 6.6 | 16.0 | 21.7 |
| 6.6 | 11.6 | 16.5 |
| 11.6 | 24.6 | 27.7 |
| 71.7 | 29.5 | 21.8 |
| 30.6 | 16.7 | 13.0 |
| 219.4 | 143.2 | 35.4 |
| | 10,208 2,077 808 6.6 6.6 11.6 71.7 30.6 | 10,208 15,265 2,077 3,750 808 1,965 6.6 16.0 6.6 11.6 11.6 24.6 71.7 29.5 30.6 16.7 |

Source: Company, Bloomberg, BOBCAPS Research

Stock performance



Source: NSE





Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above

Rating distribution

As of 28 February 2022, out of 115 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 65 have BUY ratings, 29 have HOLD ratings, 5 are rated ADD*, 1 is rated REDUCE* and 15 are rated SELL. None of these companies have been investment banking clients in the last 12 months. (*Our ADD and REDUCE ratings are in the process of being migrated to the new recommendation structure.)

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996GOI098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed

EQUITY RESEARCH 07 March 2022

FIRST LIGHT



in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

EQUITY RESEARCH 07 March 2022